Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neovasc Inc. NVCN

Healthcare Medical Instruments & Supplies
Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter... see more

Recent & Breaking News (NDAQ:NVCN)

Neovasc Announces Circulatory System Devices Panel Meeting Date for Neovasc Reducer(TM) Device

GlobeNewswire July 9, 2020

Neovasc Provides Update on Second Quarter Results

GlobeNewswire July 6, 2020

Neovasc Reducer(TM) and Tiara(TM) Featured at Leading Industry Virtual Conferences

Newsfile June 29, 2020

Neovasc Announces Positive Interim Results from REDUCER-I Study

GlobeNewswire June 26, 2020

Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

Newsfile June 25, 2020

Neovasc Announces Closing of $11.5 Million Registered Direct Offering Priced At-The-Market

GlobeNewswire June 16, 2020

Neovasc Announces $11.5 Million Registered Direct Offering Priced At-The-Market

GlobeNewswire June 12, 2020

Neovasc Reducer(TM) and Tiara(TM) Program to be Highlighted at Leading Industry Virtual Conferences

GlobeNewswire June 9, 2020

Neovasc Announces Closing of Final Convertible Debt Issuance for Gross Proceeds of US$5.0 Million

GlobeNewswire June 4, 2020

Neovasc Reducer Spotlighted in Leading German Public Television Program

GlobeNewswire June 3, 2020

Neovasc Has Filed for CE Mark for Tiara TA Transapical Mitral Valve Replacement System

GlobeNewswire May 27, 2020

Neovasc Provides Corporate Update

GlobeNewswire May 26, 2020

Neovasc Announces Offering of Convertible Debt and Warrants for Gross Proceeds of up to US$5.0 Million, Warrant Exchange Transaction and Repayment of 2017 Convertible Notes and Related Settlement

GlobeNewswire May 26, 2020

Neovasc Announces First Quarter Financial Results

GlobeNewswire May 7, 2020

Neovasc Announces Receipt of Nasdaq Extension to Satisfy Market Cap Rule

GlobeNewswire May 1, 2020

Neovasc to Report First Quarter Financial Results on May 7, 2020

GlobeNewswire April 23, 2020

Neovasc Announces Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire March 30, 2020

Neovasc to Report Fourth Quarter and Full Year 2019 Financial Results on March 30, 2020

GlobeNewswire March 17, 2020

Neovasc Updates Investors at SVB Leerink 9th Annual Global Healthcare Conference

GlobeNewswire March 4, 2020

Neovasc Reducer Featured in Peer Reviewed EuroIntervention and PCR Online

GlobeNewswire March 3, 2020